IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 250 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $133 | -35.4% | 29,200 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $206 | +35.5% | 29,200 | +17.3% | 0.00% | 0.0% |
| Q1 2023 | $152 | -4.4% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $159 | -99.9% | 24,900 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $239,000 | -13.1% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $275,000 | -33.7% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $415,000 | -12.6% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $475,000 | -22.6% | 24,900 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $614,000 | -5.2% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $648,000 | -17.8% | 24,900 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $788,000 | -31.8% | 24,900 | 0.0% | 0.00% | -42.9% |
| Q4 2020 | $1,155,000 | +71.1% | 24,900 | +21.5% | 0.01% | +40.0% |
| Q3 2020 | $675,000 | -40.1% | 20,500 | -50.0% | 0.01% | 0.0% |
| Q2 2020 | $1,126,000 | – | 41,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |